AstraZeneca Drug Raises Diabetes Risk, Doctor SaysPrint This Post
By Sophia Pearson and Doris Bloodsworth
Jan. 16, 2008
AstraZeneca Plc’s antipsychotic drug Seroquel raised by almost 400 percent the risk of developing diabetes when compared with first-generation medications in its class, a doctor testified in a court case against the drugmaker.
A 2004 article published in Psychiatric Services, a journal of the American Psychiatric Association, reported the increased risk in males who were exposed to Seroquel for at least 60 days. The study, which involved 1,629 patients, compared the exposure of a newer class of antipsychotics including clozapine and Seroquel with an older class of drugs, Jennifer Marks, a Miami- based endocrinologist, said during a pre-trial hearing yesterday in federal court in Orlando, Florida.
“Seroquel is a substantial factor in diabetes and weight gain,” Marks said, noting the 389 percent rise.
AstraZeneca, the U.K.’s second-largest drugmaker, faces about 9,000 lawsuits in the U.S. over claims Seroquel causes diabetes and other health problems. Seroquel, which generated sales of $4.03 billion in 2007, is the London-based company’s second-biggest seller after the ulcer treatment Nexium. Marks testified on behalf of former Seroquel user Linda Guinn, the first case to come to trial over the drug.
More here: http://www.bloomberg.com/apps/news?pid=20601202&sid=av_Gg66oOeWA&refer=healthcare
28,093 Signatures Against TeenScreen. Petition: http://www.petitiononline.com/TScreen/petition.html